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Transcatheter aortic valve replacement (TAVR) has successfully demonstrated its efficacy 
and safety as an alternative therapy to surgical aortic valve replacement not only in high or 
intermediate risk patients but also in low risk patients with severe aortic valve stenosis.1)2) 
However, TAVR is associated with morbidities such as paravalvular leak (PVL), conduction 
abnormalities, and vascular complications.2)3) Sapien valve system (Edwards Lifesciences, 
Irvine, CA, USA) was the first commercially available TAVR prosthesis for clinical use.4) 
Sapien 3 is the latest generation valve currently available in Korea. Whereas the previous 
generation Sapien XT used an introducer sheath of 16–18F diameter, Sapien 3 requires a 
lower profile sheath of 14–16F. In addition, Sapien 3 added an outer sealing skirt made of 
polyethylene terephthalate to minimize paravalvular leak.
In this issue of Korean Circulation Journal, Kook et al.5) reported outcomes of Sapien 3 in 
TAVR in Korean patients compared with Sapien XT. In their study, Sapien 3 showed a 
higher device success rate and a lower incidence of moderate or severe PVL than Sapien 
XT. The 1-year cardiovascular mortality rate was also lower with Sapien 3. This study has 
limitations including retrospective study design, small sample size, inadequate adjustment of 
confounding factors, especially learning curve of procedure skills and difference experience 
levels among participating centers. Despite these limitations, the findings of the study are 
generally consistent with the previous reports.6)7) A recent meta-analysis study demonstrated 
that Sapien 3 achieved higher rates of device success and lower rates of moderate or severe 
PVL, major vascular complications, major bleeding, stroke, and early mortality than Sapien 
XT.6) Thus, the lower delivery system profile and the outer skirt of the Sapien 3 appear to 
successfully reduce procedure-related complications and significant PVL and to improve 
the device success. However, permanent pacemaker implantation rate was higher after 
implantation of Sapien 3 rather than Sapien XT. The outer skirt of Sapien 3 may be helpful 
to reduce PVL, however it seems to induce more atrioventricular conduction abnormality 
as a trade-off. However, in the present study, the pacemaker implantation rate was very low 
for both Sapien XT and Sapien 3 (2.1% vs. 1.1%, p=0.621). Whether operator techniques 
or patient ethnicity might contribute to the low permanent pacemaker implantation rate 
remains unknown.
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► See the article “Comparing the Procedural and Clinical Outcomes of Sapien XT and Sapien 3 Valves in 
Transcatheter Aortic Valve Replacement in Korean Patients” in volume 50 on page 907.
Kook et al.5) reported in this study that the effective orifice area of the implanted valve was 
smaller with Sapien 3 than Sapien XT and suggested that the outer skirt of Sapien 3 might 
cause a smaller effective orifice area. Similar findings have been also observed in the other 
studies. Abdelghani et al.8) speculated lesser valve oversizing as another explanation for the 
smaller effective orifice area (EOA) with Sapien 3. They described that there was a significant 
decline of percentage oversizing of the balloon expanding valves from 11.4% with Sapien XT 
to 3.7% with Sapien 3 despite similar manufacturer's sizing recommendation. The authors 
explained that the data on annulus rupture by excessive oversizing in cases of Sapien XT 
might have contributed in part to more conservative approach in valve sizing since Sapien 3 is 
capable to reduce PVL with the outer sealing skirt. Thus, from the safety point of view, lesser 
oversizing of the Sapien 3 appears to be appropriate. However, smaller EOA is associated with 
a higher residual transvalvular pressure gradient and a higher incidence of patient-prosthesis 
mismatch (PPM) especially in cases of small valve sizes. Theron et al.9) demonstrated that the 
risk of PPM is increased with 23 mm Sapien 3 in comparison with 23 mm Sapien XT. PPM has 
been shown to be associated with an increase in all-cause and cardiac-related mortality over 
long-term follow-up.10) Therefore, Sapien valve system needs to find a solution to increase the 
EOA and thereby to reduce the risk of PPM especially in cases of small valve sizes.
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